California Biomedical Community Honors Congresswoman Anna Eshoo

LA JOLLA, Calif.--(BUSINESS WIRE)-- Congresswoman Anna G. Eshoo (D – Palo Alto) was honored by the California Healthcare Institute (CHI) with the organization’s first-ever Champion for California Life Sciences Innovation award. The award was presented by CHI Chairman George Scangos, president & CEO, Exelixis; David Gollaher, president and CEO, CHI; David Beier, senior vice president, Global Government and Corporate Affairs, Amgen; William Rhodes, worldwide president, BD Biosciences; Bernardus N.M. Machielse, executive vice president, Operations, MedImmune; and John Martin, chairman and CEO, Gilead Sciences, at a CHI dinner in Washington, D.C.

“Congresswoman Eshoo has been a tireless champion for American competitiveness, biomedical innovation and access to healthcare,” said David Gollaher, Ph.D., CHI’s president and chief executive officer. “As Congress worked to enact healthcare reform legislation, Anna led efforts to address concerns with the equity and fairness of the medical device tax and was the primary author of language to enact a science-based biosimilars pathway at the U.S. Food and Drug Administration to promote competition while fostering continued investment and innovation.”

"Innovation and competition are the key components to expanding our medical universe and allowing homegrown companies to thrive and develop life-saving treatments for patients,” Eshoo said. “I am deeply honored to be recognized by CHI for my work in support of the life sciences which I believe will make the 21st century an American century.”

About CHI

CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s Web site is www.chi.org. Follow us on Twitter @calhealthcare and Facebook.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6281468&lang=en



CONTACT:

California Healthcare Institute
Nicole Beckstrand
858-456-8881
858-401-2897
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo
Photo
 Photo
(from left) John Martin (Gilead Sciences), Bernardus N.M. Machielse (MedImmune), William Rhodes (BD Biosciences), Congresswoman Anna G. Eshoo, David Beier (Amgen), David Gollaher (CHI), and George Scangos (Exelixis) (Photo: Business Wire)

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.